Cigna Stock – Too Cheap to Ignore – FAST Graphs

2021-08-09

Cigna Stock – Too Cheap to Ignore

On August 5, 2021, Cigna (CI) shares fell approximately 11%, which caused a lot of concern for investors. However, the news actually caused me confusion because Cigna reported that earnings beat by $0.27 and so did revenues. Consequently, I felt that the change in fundamentals that certain analysts are concerned about hardly warrant an 11% drop. Therefore, I consider Cigna currently attractive with a solid margin of safety and an opportunity to generate double digit rewards. As a kicker, the company has started paying a dividend which would further add to the opportunity to now invest in this stock now that it’s undervalued.

FAST Graphs Analyze Out Loud Video:

FAST Graphs Analyze Out Loud Video

Try FAST Graphs for FREE Today!

SUBSCRIBE to our YouTube Channel

Click here for our Research Articles

Disclosure: Long CI at the time of writing.

Disclaimer: The opinions in this document are for informational and educational purposes only and should not be construed as a recommendation to buy or sell the stocks mentioned or to solicit transactions or clients. Past performance of the companies discussed may not continue and the companies may not achieve the earnings growth as predicted. The information in this document is believed to be accurate, but under no circumstances should a person act upon the information contained within. We do not recommend that anyone act upon any investment information without first consulting an investment advisor as to the suitability of such investments for his specific situation.

Unlock data on thousands of companies

Disclaimers: F.A.S.T. Graphs, Inc. is not a broker-dealer or a registered investment adviser. Under no circumstances does any information on Fastgraphs.com constitute a recommendation to buy or sell a security, nor does it give investment advice. This is to include any publications or articles on Fastgraphs.com. Fastgraphs.com is a research tool to be used by its subscribers in conjunction with the subscribers’ additional research and due diligence. The information on this site is in no way guaranteed for completeness or accuracy.